Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marshall A Corson

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Cardiology Reports|October 30, 2009
Emerging inflammatory markers for assessing coronary heart disease riskMarshall A Corson
Therapeutic Advances in Cardiovascular Disease|July 28, 2010
Darapladib: an emerging therapy for atherosclerosisMarshall A Corson
Lancet (London, England)|February 24, 2009
Phospholipase A2 inhibitors in atherosclerosis: the race is onMarshall A Corson
Current Treatment Options in Cardiovascular Medicine|July 24, 2008
Use of biomarkers to develop treatment strategies for atherosclerosisMark A Crandall, Marshall A Corson
Idrugs : the Investigational Drugs Journal|October 1, 2009
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery diseaseRobert F Riley, Marshall A Corson
The American Journal of Cardiology|July 25, 2008
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk markerMarshall A Corson, Peter H Jones, Michael H Davidson
The American Journal of Medicine|September 30, 2009
Right rhythm, right patient, right ventricleAlec J Moorman, Marshall A Corson, Zachary D Goldberger
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|February 18, 2003
Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptinKevin D Niswender, Byron Gallis, James E Blevins, et al.
Journal of Molecular and Cellular Cardiology|June 28, 2005
Activation of IKKbeta by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cellsFrancis Kim, Kelly A Tysseling, Julie Rice, et al.
The American Journal of Cardiology|July 25, 2008
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelinesMichael H Davidson, Marshall A Corson, Mark J Alberts, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Cardiology Reports|October 30, 2009
Emerging inflammatory markers for assessing coronary heart disease riskMarshall A Corson
Therapeutic Advances in Cardiovascular Disease|July 28, 2010
Darapladib: an emerging therapy for atherosclerosisMarshall A Corson
Lancet (London, England)|February 24, 2009
Phospholipase A2 inhibitors in atherosclerosis: the race is onMarshall A Corson
Current Treatment Options in Cardiovascular Medicine|July 24, 2008
Use of biomarkers to develop treatment strategies for atherosclerosisMark A Crandall, Marshall A Corson
Idrugs : the Investigational Drugs Journal|October 1, 2009
Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery diseaseRobert F Riley, Marshall A Corson
The American Journal of Cardiology|July 25, 2008
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk markerMarshall A Corson, Peter H Jones, Michael H Davidson
The American Journal of Medicine|September 30, 2009
Right rhythm, right patient, right ventricleAlec J Moorman, Marshall A Corson, Zachary D Goldberger
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|February 18, 2003
Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptinKevin D Niswender, Byron Gallis, James E Blevins, et al.
Journal of Molecular and Cellular Cardiology|June 28, 2005
Activation of IKKbeta by glucose is necessary and sufficient to impair insulin signaling and nitric oxide production in endothelial cellsFrancis Kim, Kelly A Tysseling, Julie Rice, et al.
The American Journal of Cardiology|July 25, 2008
Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelinesMichael H Davidson, Marshall A Corson, Mark J Alberts, et al.
Pageof 2